Alliancebernstein L.P. Has $490,000 Position in Novavax, Inc. (NASDAQ:NVAX)

Alliancebernstein L.P. raised its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 39.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 425,701 shares of the biopharmaceutical company’s stock after acquiring an additional 121,200 shares during the quarter. Alliancebernstein L.P. owned approximately 0.15% of Novavax worth $490,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the company. HighTower Advisors LLC boosted its stake in shares of Novavax by 3.8% during the 1st quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 5,250 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Novavax by 2.7% during the 1st quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock worth $440,000 after acquiring an additional 8,966 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Novavax by 0.9% during the 1st quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock valued at $1,555,000 after buying an additional 10,347 shares in the last quarter. American International Group Inc. lifted its stake in shares of Novavax by 7.1% during the 1st quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 10,965 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Novavax by 7.2% during the 2nd quarter. Rhumbline Advisers now owns 346,968 shares of the biopharmaceutical company’s stock valued at $399,000 after buying an additional 23,410 shares in the last quarter. Institutional investors and hedge funds own 38.87% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Alliancebernstein L.P. Has $490,000 Position in Novavax, Inc. (NASDAQ:NVAX)” was originally reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.truebluetribune.com/2017/11/14/alliancebernstein-l-p-raises-position-in-novavax-inc-nvax.html.

A number of research analysts recently weighed in on NVAX shares. Citigroup Inc. upgraded shares of Novavax from a “neutral” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Tuesday, October 31st. BidaskClub cut shares of Novavax from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Zacks Investment Research cut shares of Novavax from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Ladenburg Thalmann Financial Services upgraded shares of Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price target on the stock in a research note on Wednesday, August 9th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $2.00 target price on shares of Novavax in a report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $3.12.

Novavax, Inc. (NASDAQ NVAX) opened at $1.22 on Tuesday. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31. Novavax, Inc. has a one year low of $0.73 and a one year high of $1.78.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The firm had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.42 million. During the same quarter in the prior year, the company earned ($0.24) EPS. The company’s revenue was up 158.5% compared to the same quarter last year. equities research analysts expect that Novavax, Inc. will post -0.61 EPS for the current year.

In other Novavax news, Director James F. Young sold 175,000 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $1.06, for a total transaction of $185,500.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Stanley C. Erck purchased 100,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $1.13 per share, for a total transaction of $113,000.00. Following the purchase, the insider now directly owns 228,279 shares in the company, valued at approximately $257,955.27. The disclosure for this purchase can be found here. Corporate insiders own 4.00% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply